An observational study in Infertility, Infertility, Female and Anovulation, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 34 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Assiut University · Observational
This prospective cohort study aims to compare the effectiveness of half-dose (0.125 mg/day) versus conventional-dose (0.25 mg/day) cetrorelix in GnRH antagonist ICSI cycles regarding clinical pregnancy rate in women with BMI ≥25 kg/m².
Cetrorelix is used as a GnRH antagonist to prevent premature LH surge during controlled ovarian stimulation for ICSI. This observational study will include women aged less than 35 years with normal ovarian reserve and BMI ≥25 kg/m² who received either half-dose or conventional-dose cetrorelix as part of routine care. Clinical pregnancy rate and secondary reproductive outcomes will be compared between the two groups.
552 studies on the registry are indexed under Infertility, Female; 137 are open to participants now.
This study's planned enrollment of 160 is close to the median of 161 across 162 observational studies indexed under Infertility, Female.
Browse Infertility, Female studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Infertility, Female, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Women aged less than 35 years with BMI ≥25 kg/m² and normal ovarian reserve who received either half-dose or conventional-dose cetrorelix as part of routine care during GnRH antagonist ICSI cycles at Assiut University Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women who received cetrorelix 0.125 mg daily as part of routine GnRH antagonist protocol.
Women who received cetrorelix 0.25 mg daily as part of routine GnRH antagonist protocol.
Clinical Pregnancy Rate
Proportion of women with intrauterine gestational sac with fetal heartbeat by ultrasound at 6 weeks gestation
Time frame: 6 weeks after embryo transfer
Ongoing pregnancy rate
Ongoing pregnancy with heartbeat \>12 weeks on ultrasound
Time frame: 12 weeks after embryo transfer
Number of retrieved oocytes
Mean number of oocytes retrieved at pickup
Time frame: Periprocedurally, at time of oocyte retrieval, during oocyte pickup procedure
Number of mature MII oocytes
Mean number of mature MII oocytes
Time frame: Periprocedurally , at time of oocyte retrieval, Day 0, during oocyte pickup procedure
Fertilization rate
Fertilized oocytes / MII oocytes
Time frame: 1 day after ICSI
Premature LH surge
LH \>=10 IU/L or progesterone \>=1.0 ng/mL before trigger
Time frame: Baseline (before hCG trigger)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 85 non-industry observational studies under Infertility, Female, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 69. This study's planned 12 months is below that.
Counting every sponsor, half of 88 studies reached it within 36 months; a quarter within 18 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.